Key Takeaways
- CMS drove the beat, GDS lagged: CMS volumes picked up beyond expectations, making it the dominant segment this quarter, while specialty GDS was a little shy of expectations.
- Balance sheet transformed to net cash: Net debt stands at negative ₹39.4 crores, working capital debt is zero, and the working capital cycle compressed to 102 days from 118 days sequentially.
- Pipeline deepening at later stages: Phase-2 project revenue doubled, and the pipeline of near-commercial CMS molecules sits with biotech companies, carrying exclusivity through patent expiries only after 2030.
- Peptide business still a call option: After 14 years, management admits the business has not contributed significantly and attributes the gap to underinvestment in development capabilities.
- What to watch next quarter: Whether the GDS softness reverses, any CAPEX decisions from the board on growth opportunities flagged for the next 2-4 quarters, and lead indicators on peptide NCE progress.
CMS: The Quarter's Engine
- Volume-driven outperformance: CMS volumes picked up beyond expectations, pushing the segment ahead of GDS in the revenue mix; management called out the natural transition from prime APIs into a CMS and specialty GDS focused business over the last two years.
- Recurrence, not one-offs: Commercial CMS orders carry a degree of recurrence, and the doubling of Phase-2 revenue signals new molecules entering commercialization, not a one-time spike. Growth will continue but the quantum cannot be indicated.
- Pipeline built for exclusivity: 7-8 near-commercial APIs sit with biotech companies, spanning chronic and acute therapies, many in CNS. Patent expiries only start after 2030, so the next 7 years or so should continue to see the exclusivity benefit.
- Competitive insulation: In the top 10 molecules, none have overlapping competitors, and in the pipeline of new CMS projects, no two projects share the same competitors in the bidding process.
Saharsh Davuluri: "the patent expiries only start after 2030. So, the other comfort that we draw from our CMS pipeline is that next 7 years or so we should continue to see the exclusivity benefit us."
GDS & the Specialty Mix
- Specialty dipped, half-year on track: Specialty revenues saw a slight dip this quarter, but H1 growth was on expected lines, driven by Paliperidone, Apixaban and Donepezil. The Prime segment was driven by Mirtazapine and growth of Escitalopram business.
- Funding crunch filters the pipeline: Early-stage projects and those with weak clinical data lost momentum as funding tightened. New customers are arriving with later-stage assets, Phase-2 and beyond, looking for reliable API partners, which raises pipeline quality.
- No one-offs in the base: Management confirmed the business does not have any significant one-offs even this quarter, so the GDS softness reflects underlying mix rather than a comp issue.
Balance Sheet & Capital Allocation
- Net cash achieved: Net debt moved to negative ₹39.4 crores, working capital debt was eliminated, and the working capital cycle improved by 16 days QoQ to 102 days.
- CAPEX run-rate: ₹43 crores invested in the quarter; regular annual CAPEX is expected at ₹100-₹120 crores, with flexibility to go higher if an opportunity with a certain level of certainty arises.
- Growth CAPEX decision pending: Some action on capital allocation for growth is expected in the next 2-4 quarters, but it needs board placement and internal discussion first.
- Capacity creation tied to visibility: Future investments will be made based on shared visibility from clients; management will not create large capacities without business visibility. GDS and multiproduct facility CAPEX will be based on best estimates without signed contracts, while R&D labs, pilot plants and scale-up facilities are investments the company makes on its own.
Saharsh Davuluri: "the decision to make CAPEX investments based on visibility that we get from customers is actually a position of privilege that we have put ourselves over the years of building this business."
Peptides: A Long Gestation
- Organic, slow build: Entry began in 2009 with building blocks, progressed to peptide fragments for European CDMOs, then innovator peptide APIs (NCEs), and now peptide generic API development. Two European Big Pharma companies work with Neuland on peptide projects because typical Big Pharma suppliers do not focus on peptides.
- Admission of underinvestment: Management acknowledged the business has not contributed significantly, attributing it partly to not putting enough emphasis on development capabilities, and that none of the 14-15 peptide projects made it to commercial success.
- Lead indicators only: Work continues on exciting peptides in the NCE space and a DMF for generics, but revenue will only be heard when business comes in; until then, only lead indicators appear in commentary.
Saharsh Davuluri: "I think it is fair to also admit that the business itself has not contributed significantly to us. I would probably attribute that to two things. One is could we have put in a greater emphasis in terms of development capabilities and maybe develop more molecules, the answer to that is definitely yes..."
Operating Model & Competitive Position
- Lumpiness is structural: Quarter-to-quarter volatility is expected due to the nature of the business and customer delivery requirements; some sales cycles and manufacturing campaigns are so long that volatility can spill into the next year. Growing scale will not necessarily change these inherent qualities.
- Swimming in an ocean: Management sees the CDMO space as a $60-$70 billion market where no player exceeds $2-$3 billion in size, so Neuland hardly sees any competition.
- Customer retention as moat: The company has hardly lost a customer in the last two decades, with a customer-centric approach central to its strategy.
- Unit 3 headroom: Utilization sits at 60-65%, and the campus is large enough to create more facilities; capacity can be created within roughly 12 months from a decision.
Sucheth Davuluri: "we have hardly lost a customer in the last two decades, so I think customer is the center of our focus"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Regular CAPEX | ₹100-₹120 crores annually | Ongoing |
| Growth CAPEX decision | Some action expected; needs board placement | Next 2-4 quarters |
| CMS pipeline exclusivity | Patent expiries only after 2030 | Next ~7 years |
| Unit 3 capacity creation | Can create capacity within 12 months of decision | 12 months from decision |
| CMS commercial molecules | Maybe 2-3 more molecules could get commercialized | Next 2 years |
| Peptide revenue | Music will be heard when business comes in | No timeline (lead indicators only) |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Total income | ₹420.8 cr, vs ₹293.9 cr in Q2 FY23 |
| Gross margin | 59.8%, vs 56.2% in Q2 FY23 and 55.2% in Q1 FY24 |
| Profit after tax | ₹89.1 cr, vs ₹38.3 cr in Q2 FY23 |
| EPS | ₹69.4 per share |
| Free cash flow | ₹128.8 cr (H1 FY24) |
| Net debt position | negative ₹39.4 cr, more than a zero-debt company |
| Working capital cycle | 102 days, improved from 118 days in Q1 FY24 |
| CAPEX invested | ₹43 cr (during the period) |
| Regular CAPEX guidance | ₹100–₹120 cr annually |
| CMS share of topline | 55%, up from 45% (implied jump) |
| Unit 3 utilization | 60%–65% of current installed capacity |
| CMS commercial molecules actively contributing | 5 or 6 |
| Phase-2 to commercialization conversion rate | 25%, roughly one in four molecules |
| CMS pipeline patent expiry | after 2030, providing exclusivity for the next 7 years or so |